313 related articles for article (PubMed ID: 36520421)
1. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review.
Petty WJ; Paz-Ares L
JAMA Oncol; 2023 Mar; 9(3):419-429. PubMed ID: 36520421
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy.
Ragavan M; Das M
Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742
[TBL] [Abstract][Full Text] [Related]
3. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
4. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
Das M; Padda SK; Weiss J; Owonikoko TK
Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
[TBL] [Abstract][Full Text] [Related]
5. Lurbinectedin for the treatment of small cell lung cancer.
Li L; Zou C; Dong S; Wu ZX; Ashby CR; Chen ZS; Qiu C
Drugs Today (Barc); 2021 Jun; 57(6):377-385. PubMed ID: 34151904
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatments of small-cell lung cancers.
Baize N; Monnet I; Greillier L; Quere G; Kerjouan M; Janicot H; Vergnenegre A; Auliac JB; Chouaid C
Expert Rev Anticancer Ther; 2017 Nov; 17(11):1033-1043. PubMed ID: 28849951
[TBL] [Abstract][Full Text] [Related]
7. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Horn L; Reck M; Spigel DR
Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review.
Zhang X; Zheng J; Niu Y; Xue C; Yu Y; Tan K; Cui H
Front Immunol; 2022; 13():1059331. PubMed ID: 36532013
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
Xiong J; Barayan R; Louie AV; Lok BH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
Reddy HG; Qin A; Kalemkerian GP
Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
[TBL] [Abstract][Full Text] [Related]
11. Update 2021: Management of Small Cell Lung Cancer.
Tariq S; Kim SY; Monteiro de Oliveira Novaes J; Cheng H
Lung; 2021 Dec; 199(6):579-587. PubMed ID: 34757446
[TBL] [Abstract][Full Text] [Related]
12. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
13. Lurbinectedin in the treatment of relapsed small cell lung cancer.
Baena J; Modrego A; Zeaiter A; Kahatt C; Alfaro V; Jimenez-Aguilar E; Mazarico JM; Paz-Ares L
Future Oncol; 2021 Jun; 17(18):2279-2289. PubMed ID: 33736462
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC.
Niu X; Chen L; Li Y; Hu Z; He F
Semin Cancer Biol; 2022 Nov; 86(Pt 3):273-285. PubMed ID: 35288298
[TBL] [Abstract][Full Text] [Related]
15. Advances in new targets for immunotherapy of small cell lung cancer.
Zheng Z; Liu J; Ma J; Kang R; Liu Z; Yu J
Thorac Cancer; 2024 Jan; 15(1):3-14. PubMed ID: 38093497
[TBL] [Abstract][Full Text] [Related]
16. Advances in immune checkpoint inhibitors therapy for small cell lung cancer.
Li L; Liang Y; Yu M; Zhao L; Mei Q; Yu Y; Wang N; Zhang D; Wang Z; Jia Y; Kong F
Cancer Med; 2023 May; 12(10):11097-11106. PubMed ID: 36880420
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the treatment of small cell lung cancer in the era of immunotherapy and molecular classification.
Caliman E; Fancelli S; Petroni G; Gatta Michelet MR; Cosso F; Ottanelli C; Mazzoni F; Voltolini L; Pillozzi S; Antonuzzo L
Lung Cancer; 2023 Jan; 175():88-100. PubMed ID: 36493578
[TBL] [Abstract][Full Text] [Related]
18. Considerations for selecting second-line treatment in patients with progressive small cell lung cancer and the use of Lurbinectedin in this setting.
Badin F
Cancer Treat Res Commun; 2024; 39():100803. PubMed ID: 38490092
[TBL] [Abstract][Full Text] [Related]
19. Extensive-stage small-cell lung cancer: Current management and future directions.
Yu Y; Chen K; Fan Y
Int J Cancer; 2023 Jun; 152(11):2243-2256. PubMed ID: 36346100
[TBL] [Abstract][Full Text] [Related]
20. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
